Regulatory Spine Karolinska Development’s portfolio company OssDsign has received FDA clearance for a new major indication byJosh SandbergSeptember 19, 2023
Biologics Spine 2,000 patients treated with OssDsign® Catalyst in the U.S. byJosh SandbergSeptember 13, 2023
Spine OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL byJosh SandbergAugust 17, 2023
